Eisai Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Research-and-Development" stands at 165.40 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 12/31/2021.
Eisai Co. Ltd.'s second quarter result of 36.74 Billion JPY for the item "Research and Development" represents a decrease of -5.30 percent compared to it's first quarter result.
Also, Eisai Co. Ltd.'s second quarter result of 36.74 Billion JPY for the item "Research and Development" represents a decrease of -8.22 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Eisai Co. Ltd.'s second quarter result of 165.40 Billion JPY for the item "Research and Development" represents a decrease of -1.95 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -1.55 percent compared to the value the year prior.
The 1 year change in percent is -1.55.
The 3 year change in percent is -4.57.
The 5 year change in percent is 18.46.
The 10 year change in percent is 24.68.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Research and Development | 905,699,262,464.00 |
![]() | Johnson & Johnson - Research and Development | 486,508,953,600.00 |
![]() | AbbVie Inc - Research and Development | 399,570,305,024.00 |
![]() | Roche Holding AG - Research and Development | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Research and Development | 280,205,508,085.11 |